LAMATTINA JOHN L
Known title: DirectorCIK: 0001216074
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Immunome files Nasdaq inducement grant report, sees higher volume. Immunome disclosed inducement grants in a filing required by Nasdaq Listing Rule 5635(c)(4). The disclosure shows the company is meeting reporting obligations for equity compensation. At the same time, the stock appeared among Benzinga’s recent volume movers, indicating a noticeable increase in trading activity. These items together suggest regulatory compliance and heightened market attention.
Transaction History
| LGND | ▼ Sell | Open Market | 257 | $64K | 6/10/2026 | View on chart |
| LGND | ▼ Sell | Open Market | 232 | $58K | 6/10/2026 | View on chart |
| LGND | ▼ Sell | Open Market | 697 | $174K | 6/10/2026 | View on chart |
| LGND | ▼ Sell | Open Market | 3,405 | $857K | 6/10/2026 | View on chart |
| LGND | ▲ Buy | Grant | 836 | $0 | 6/5/2026 | View on chart |
| LGND | ▲ Buy | Option Exercise | 2,161 | $247K | 3/6/2026 | View on chart |
| LGND | ▼ Sell | Open Market | 2,161 | $434K | 3/6/2026 | View on chart |
| LGND | ▲ Buy | Option Exercise | 2,145 | $142K | 11/7/2025 | View on chart |
| LGND | ▼ Sell | Open Market | 2,145 | $441K | 11/7/2025 | View on chart |
| LGND | ▲ Buy | Option Exercise | 2,034 | $141K | 11/7/2025 | View on chart |
| LGND | ▼ Sell | Open Market | 2,034 | $418K | 11/7/2025 | View on chart |
| LGND | ▲ Buy | Grant | 1,209 | $0 | 6/6/2025 | View on chart |
| LGND | ▲ Buy | Option Exercise | 2,406 | $126K | 11/27/2024 | View on chart |
| LGND | ▼ Sell | Open Market | 2,406 | $298K | 11/27/2024 | View on chart |
| LGND | ▲ Buy | Grant | 1,252 | $0 | 6/14/2024 | View on chart |
| LGND | ▲ Buy | Grant | 1,142 | $0 | 6/9/2023 | View on chart |
| IMNM | ▲ Buy | Grant | 15,125 | $61K | 1/15/2023 | View on chart |
| LGND | ▲ Buy | Grant | 1,004 | $0 | 6/10/2022 | View on chart |
| LGND | ▲ Buy | Option Exercise | 4,835 | $156K | 11/16/2021 | View on chart |
| LGND | ▼ Sell | Open Market | 4,835 | $783K | 11/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Ligand Pharmaceuticals Releases Q2 2026 Earnings Call Transcript
Ligand Pharmaceuticals has published the full transcript of its second-quarter 2026 earnings call, providing investors with detailed management commentary on recent performance. While the stock currently trades near a key support level, the release of this transcript offers a deeper look into the company's operational updates and strategic outlook beyond the headline financial figures.
Ligand Pharmaceuticals Releases Q2 2026 Earnings Call Transcript. Ligand Pharmaceuticals has published the full transcript of its second-quarter 2026 earnings call, providing investors with detailed management commentary on recent performance. While the stock currently trades near a key support level, the release of this transcript offers a deeper look into the company's operational updates and strategic outlook beyond the headline financial figures.